Morecare Transfusion Medicine Inc. Completes Tens-of-Millions RMB Angel Round to Pioneer Standardized Pet Blood Solutions

Amid macroeconomic headwinds, the pet industry has bucked the trend to emerge as a new growth frontier at the intersection of consumption upgrading and life sciences. This phenomenon not only reflects the growing need for emotional companionship among contemporary consumers but also signals that the pet sector will continue to unlock its market potential through technological empowerment, injecting differentiated innovative vitality into economic growth.

VCBeat has learned at the earliest opportunity that,Guochong | Advanced Science Announces Its SubsidiaryGuochong Blood Technology (Jiangxi) Co., Ltd. (hereinafter referred to as “Guochong | Blood Technology” or the “Company”)Completed a tens-of-millions-yuan angel round of financing, led by Shanghai Hanwei Biopharmaceuticals and followed by Tuneng Group.Riemann-Hypothesis served as the exclusive financial advisor for this round and provided comprehensive financing strategy support throughout the process.

Public information from the Market Supervision Administration shows that Guochong | Blood Technology was registered in February 2025 and completed its angel financing round just three months later, demonstrating strong market recognition of its technological innovation and commercial potential.

It is reported that this round of financing will be primarily used for the research and development of high-quality pet blood products, the establishment of a standardized blood bank system, and market expansion, further solidifying its leading position in this vertical niche sector.

As a critical component of the “last mile” in veterinary care, pet blood transfusion, despite being a high-frequency life-saving intervention, has long remained in a gap characterized by “demand without standardized products.” In the face of growing needs for managing chronic diseases, performing surgical procedures, and providing emergency care in pets, the establishment of a stable, safe, and regulated blood supply system is increasingly urgent.

According to GMI Insights, the global market size for animal blood and its components reached $622.4 million in 2022 and is projected to grow to $1.5928 billion by 2032, representing a compound annual growth rate (CAGR) of 9.84%. In China, the pet healthcare market size reached RMB 73.5 billion in 2023; however, pet transfusion medicine remains in its infancy, with no established blood bank system and immature regulatory mechanisms.

AsChina’s First Standardized Integrated Solution for Pet Blood Supply and Transfusion Medicine, Guochong | Blood Technology has been committed to filling industry gaps and setting industry standards since its inception, comprehensively tackling the “uncharted territory” of building a pet blood transfusion system. Under the coordinated allocation of advanced scientific resources by Guochong, the project has already achieved a high-starting-point layout:

Jointly developed whole blood and component blood products for pets with the Institute of Blood Transfusion, Chinese Academy of Medical Sciences, and derived patented devices such as quadruple blood collection bags, anticoagulants, blood typing cards, and restraint devices.

Leveraging the Model Animal Engineering Research Center of the Gannan Institute for Innovation and Translational Medicine (equipped with SPF/A2-level animal facilities and AAALAC international accreditation, among others), we are establishing an animal blood transfusion system in accordance with human blood supply management standards.

Co-establish a clinical platform with teaching animal hospitals affiliated with leading veterinary colleges in China and abroad, conduct in-depth research on species differences and disease models in dogs and cats, and establish standardized blood transfusion protocols.

Through the deep integration of upstream technological R&D and downstream clinical implementation, Guochong | Blood Technology has systematically addressed the industry’s two core challenges—“blood supply shortages” and “insufficient standards”—establishing a replicable paradigm for pet blood platforms.

While accelerating its domestic layout, Guochong | Blood Technology is actively expanding its international cooperation network. It is reported that the company’s CEO, Kevin Yu, conducted an international technical inspection tour this May, engaging in strategic dialogues with top-tier global institutions and taking a key step toward internationalization.

During the visit, Kevin Yu held in-depth discussions with Dr. Boaz Arzi, Director of the Veterinary Institute for Regenerative Cures (VIRC), on technological R&D and clinical applications in the field of pet cell and gene therapy (CGT). During these exchanges, Guochong | Blood Technology also shared the foundational technical reserves in cell therapy developed by its parent company, Guochong | Advanced Science, thereby laying a technological foundation for future collaboration.

Furthermore, Kevin Yu conducted a special visit to the Blood Bank system founded by FDA advisory expert Dr. Julie Burges, systematically studying its transfusion medicine management system and blood bank operational paradigms that comply with international regulatory standards. This visit will help Guochong | Blood Technology refine its own management system and enhance its competitiveness in the international market.

This cross-border technological collaboration has provided forward-looking solutions for Guochong | Blood Technology to build intelligent blood centers in China, particularly by offering a localized adaptation pathway for the FDA’s mature regulatory framework, thereby injecting critical expertise into the establishment of a transfusion system that meets international certification standards.

In the future, the company will accelerate the construction of regional pet blood bank platforms, develop customized treatment protocols, and explore pathways for international expansion, thereby creating a globally competitive “Chinese Solution.”

Han Zhihong, Chairman of Shanghai Hanwei Biotechnology, stated:“Since its establishment in 2008, Shanghai Hanwei has become a leading pet pharmaceutical company in China through nearly two decades of relentless efforts. Its drug brand, ‘Hanwei Pet Care,’ is now sold in over 10,000 veterinary hospitals, maintaining a growth rate of more than 20%. By pursuing a dual strategy of domestic and international expansion, the company has successfully entered overseas markets, becoming one of the few Chinese pet pharmaceutical enterprises with a global presence.”

Our long-term dedication to the pet hospital sector has given us deep insight into numerous unmet clinical needs within the industry, with pet transfusion medicine being one of the most significant pain points. Investing in Guochong | Blood Technology aligns with our strategic plan to expand our pipeline by seeking out new technologies that possess strong scientific attributes and address critical industry challenges. We are highly enthusiastic about supporting Guochong | Advanced Science as it expands into the global market.”

Wang Ping, Chairman of Tuneng Group, stated:“National Favorite | The founding team of the blood technology venture is an exceptional group with a fully closed-loop capability across multiple dimensions, including basic research, proof of concept, clinical application, continuous R&D, and commercial operations. We have full confidence that, leveraging national-level scientific research institutions and China’s most authoritative blood transfusion research institute, they will create an innovative business model project with high-tech barriers in a blue-ocean niche within this red-ocean industry.”

Guochong | Professor Liu Jiaxin, Chief Scientist of Blood Technology and former Director of the Institute of Blood Transfusion at the Chinese Academy of Medical Sciences, stated:“Thank you to the investors for their trust and support in the company. Since retiring from the Institute of Blood Transfusion, I have served as Vice Chairman of the Chinese Society of Blood Transfusion, maintaining a strong focus on advancements in transfusion medicine. I am particularly optimistic about the future of veterinary transfusion medicine. Leveraging my decades of professional experience, I hope to help the company further refine its systems and drive technological innovation in this field. Humans and pets share the same world and deserve equal access to the same medical technologies.”

Professor Zhang Xin, Executive Dean of the Gannan Institute for Innovation and Translational Medicine, stated:“National Favorite | Blood Technology is a high-tech enterprise comprehensively empowered by our Research Institute. We are delighted to see the company secure strategic investment. As the primary supporting institution for this national-level scientific research platform, the Institute will provide enhanced support in areas such as industry standard-setting, compliance development, and sustainable R&D. We hope that the pet industry will soon establish a standardized clinical blood-use system aligned with human blood management standards, thereby benefiting more ‘furry friends.’”

Dr. Li Chaoxing, Chairman of Riemann-Hypothesis, stated:Guochong Advanced Sciences has bridged the entire chain of pet healthcare, from upstream scientific research to downstream clinical applications. With continuous and efficient technological iteration and development, the company is actively expanding its global footprint, initially penetrating the market through blood technology solutions, thereby generating significant future expectations. Meanwhile, we also anticipate that Guochong Advanced Sciences will continue to translate its other technological innovations into practical applications, venturing into more untapped blue-ocean markets.

With the mission of “filling gaps and setting standards,” Guochong | Blood Technology is leading China’s pet transfusion industry through a critical turning point—from “having gaps” to “having standards”—and ushering in a new chapter in the blue-ocean sector of veterinary care. Driven by the parent company’s strategic direction and bolstered by capital support, this project is poised to guide the pet transfusion industry in China and globally into a new era of professionalism and standardization.

Shanghai Hanwei Biopharmaceutical Technology Co., Ltd. was established in 2008. It is an international high-tech enterprise integrating the research and development, production, and sales of pet healthcare products, and has been recognized as a National High-Tech Enterprise for three consecutive terms. As of April 2025, Hanwei Pet Care has obtained 12 national new veterinary drug certificates and 46 pet drug approval numbers, with more than 50 products in its R&D pipeline.

Since its establishment, Hanwei Pet Care has consistently upheld the corporate values of “Customer First, Partner Growth.” The company has deeply cultivated the pet pharmaceutical sector, focusing on anti-infectives, dermatology, urology, antipyretic and analgesic agents, and internal and external parasiticides. It is dedicated to providing customers with novel pet-specific medications, healthcare and nursing products, and professional services. To date, Hanwei has successfully developed more than 50 pet-specific products across a comprehensive range, becoming the trusted choice for over ten thousand professional veterinary hospitals. According to data presented in the “2025 White Paper on China’s Pet Pharmaceuticals” published by Frost & Sullivan, Hanwei Pet Care ranks first among domestically produced pet pharmaceutical brands in terms of offline store coverage in China.

Rooted in China, with a Global Vision. Hanwei Pet Care products have achieved GMP certification in multiple countries and are marketed in five overseas nations. Committed to safeguarding global pet health with professionalism, Hanwei Pet Care works alongside industry peers to build a harmonious world where humans and pets thrive together.

Tuneng Group is a diversified, integrated enterprise. Its business portfolio spans genetic health screening, dietary nutrition and tonics, inspection and testing services, veterinary diagnosis and treatment, laboratory design and renovation, production and sales of reagents and consumables, sales of medical devices and equipment, as well as import and export agency services.

In 2021, a subsidiary of the Group was successfully listed and displayed on the Jiangxi United Equity Exchange Center. Leveraging its outstanding industry influence, it was successively elected as Vice-Chairman Unit of the Jiangxi Provincial Society of Animal Husbandry and Veterinary Medicine, Vice-Chairman Unit of the Jiangxi Pet Industry Association, Vice-Chairman Unit of the Jiangxi Pig Farming Industry Association, and Vice-Chairman Unit of the Jiangxi Gan Cuisine Industry Development Promotion Association, among other learned societies and associations.

The Group is currently dedicated to investment and strategic layout across multiple sectors, operating five core business segments: Life & Health, Animal Inspection Technology, Design & Renovation, Research Services, and Investment Sharing. These segments work in synergy to achieve common growth, aiming to provide users with a one-stop, diversified product and service experience.

Gannan Institute for Innovation and Translational Medicine is a high-end, new-type biomedical R&D institution established to meet the national strategic needs for scientific and technological innovation. It was jointly founded by Gannan Medical University and its affiliated hospitals, together with renowned expert and professor teams from home and abroad, with strong support from the Ganzhou Municipal People’s Government and the Zhanggong District People’s Government.

It hosts national-level scientific research and innovation platforms, including the State Key Laboratory for the Discovery of New Drug Targets and Development of Novel Drugs for Major Diseases, the Jiangxi Center of the National Molecular Medicine Translational Science Center, the Ministry of Education Key Laboratory for the Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, and the Clinical Research Center of the National Regional Medical Center. Additionally, it operates more than 20 other platforms and qualifications, such as the High-End R&D Institution Jointly Established through Introduction in Jiangxi Province, the Jiangxi Provincial Model Animal Research Center, the Jiangxi Provincial Engineering Research Center for Model Animals, the Jiangxi Provincial Strategic Alliance for Technological Innovation in the Model Animal Industry, and the Jiangxi Provincial Postdoctoral Innovation Practice Base.

The company has established a first-class innovative drug R&D center, a discipline development center, the Jiangxi Precision Medicine Center, a Model Animal Engineering Research Center, and a Pet Health Research Center. It is equipped with nearly 10,000 advanced scientific research instruments and facilities from both domestic and international sources. The company has built a “one-stop” full-process R&D system and industrial capabilities across three major sectors: innovative drugs, the pet industry, and high-end biological reagents. Currently, six Class I new veterinary drugs for treating conditions such as heart failure and diabetes have entered clinical trials, seven Class I new human drugs are under development, and more than 200 types of pet food have been developed, with over 100 products already on the market.

Guochong Blood Technology (Jiangxi) Co., Ltd. (Morecare Transfusion Medicine Inc., MTM) is a high-tech enterprise that leverages human transfusion medicine technology as its foundational framework, specializing in the research and development, production, and emergency blood supply services for pet whole blood, component blood, and blood-derived products.

Guided by its core value of “Sustaining Life,” the company is committed to addressing long-standing industry pain points in veterinary medicine, including blood supply shortages, infectious disease risks, and lack of standardization. It aims to build China’s first full-industry-chain platform for standardized pet blood banks and transfusion medicine, striving to become a global leader in pet blood technology.